Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 8/20 | 0.53 |
| ▸ | MMP2 | P08253 | 7/20 | 0.53 |
| ▸ | MMP1 | P03956 | 6/20 | 0.53 |
| ▸ | MMP8 | P22894 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.48 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.47 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.47 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.47 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.47 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.47 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.47 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.47 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8090956 | 1.00 | MMP9 (0.53) | MMP9MMP2MMP1MMP8ALDH1A1 | |
| SCHEMBL1273790 | 1.00 | MMP9 (0.53) | MMP9MMP2MMP1MMP8ALDH1A1 | |
| SCHEMBL1177439 | 1.00 | MMP9 (0.53) | MMP9MMP2MMP1MMP8ALDH1A1 | |
| SCHEMBL23343881 | 0.85 | MMP9 (0.56) | MMP9MMP2MMP1MMP8ALDH1A1 | |
| SCHEMBL14224779 | 0.85 | MMP9 (0.56) | MMP9MMP2MMP1MMP8ALDH1A1 | |
| SCHEMBL29338138 | 0.85 | MMP9 (0.53) | MMP9MMP2MMP1MMP8ALDH1A1 | |
| SCHEMBL6185985 | 0.83 | MMP9 (0.43) | MMP9MMP2MMP1MMP8ALDH1A1 | |
| SCHEMBL4861084 | 0.82 | MMP9 (0.51) | MMP9MMP2MMP1MMP8ALDH1A1 | |
| SCHEMBL4859637 | 0.82 | MMP9 (0.51) | MMP9MMP2MMP1MMP8ALDH1A1 | |
| SCHEMBL8433998 | 0.81 | MEN1 (0.54) | MMP9MMP2MMP1MMP8ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0824512-B1 | SYNTHESIS OF OPTICALLY ACTIVE AMINOINDANOL | BASF AG (DE) | 2000-12-20 | — | — | EP | claimed |
| EP-0824512-A1 | SYNTHESIS OF OPTICALLY ACTIVE AMINOINDANOL | BASF AKTIENGESELLSCHAFT (DE) | 1998-02-25 | — | — | EP | claimed |
| WO-1996035660-A1 | SYNTHESIS OF OPTICALLY ACTIVE AMINOINDANOL | BASF AKTIENGESELLSCHAFT (DE) | 1996-11-14 | — | — | WO | claimed |
| US-7407960-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| EP-1806346-A1 | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors | CV THERAPEUTICS, INC. (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20070004751-A1 | Substituted heterocyclic compounds | ELZEIN ELFATIH | 2007-01-04 | — | — | US | disclosed |
| US-7125876-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2006-10-24 | — | — | US | disclosed |
| US-20040152890-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2004-08-05 | — | — | US | disclosed |
| EP-0824512-B1 | SYNTHESIS OF OPTICALLY ACTIVE AMINOINDANOL | BASF AG (DE) | 2000-12-20 | — | — | EP | disclosed |
| EP-0824512-A1 | SYNTHESIS OF OPTICALLY ACTIVE AMINOINDANOL | BASF AKTIENGESELLSCHAFT (DE) | 1998-02-25 | — | — | EP | disclosed |
| WO-1996035660-A1 | SYNTHESIS OF OPTICALLY ACTIVE AMINOINDANOL | BASF AKTIENGESELLSCHAFT (DE) | 1996-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152890-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | MMP9 3056/4885MMP2 2809/4885MMP1 1983/4885 |
| US-20070004751-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | MMP9 3115/4885MMP2 2681/4885MMP1 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.